• Network Medicine Identifies Apigenin for Alzheimer’s Neuropr

  2026-07-03

  A recent study applies a network medicine framework to identify flavonoids with therapeutic potential against Alzheimer’s disease, highlighting apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) as an especially promising candidate. Integrating computational and experimental approaches, the research reveals novel neuroprotective mechanisms and key molecular targets for translational neuroscientists.

• Next-Generation Monocyte Trafficking Inhibition with MK-0812

  2026-07-02

  This thought-leadership article explores the mechanistic underpinnings and translational opportunities of targeting CCR2-mediated monocyte trafficking with MK-0812. By integrating recent advances in gut–liver axis research, especially the role of intestinal TM6SF2 in metabolic dysfunction-associated steatohepatitis (MASH), we chart a strategic path for researchers to leverage MK-0812 in advanced immunometabolic models. The discussion situates MK-0812 as a precision tool for dissecting immune-metabolic crosstalk, addresses protocol design, and outlines the evolving landscape for monocyte recruitment blockade in translational science.

• Angiotensin II Suppresses Ferroptosis, Drives Radioresistanc

  2026-07-02

  This study uncovers how local angiotensin II (Ang II) promotes radioresistance in nasopharyngeal carcinoma (NPC) by suppressing ferroptosis through the HIF-1α–HILPDA axis. The findings clarify mechanistic feedback within the tumor microenvironment and highlight promising biomarkers and intervention strategies to enhance radiotherapy efficacy in NPC.

• Technical Guidance for Hoechst 33342/PI Double Staining Kit

  2026-07-01

  The Hoechst 33342/PI Double Staining Kit enables rapid, fluorescence-based discrimination of viable, apoptotic, and necrotic cells by targeting chromatin condensation and membrane integrity changes. This kit is best suited for research workflows involving microscopy-based apoptosis and necrosis analysis, but is not appropriate for diagnostic or clinical use.

• Angiotensin II in Vascular Remodeling & Hypertension Models

  2026-07-01

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) empowers researchers to reproducibly model hypertension and vascular remodeling, with robust protocols and advanced troubleshooting support. Leveraging APExBIO's high-purity peptide, investigators can dissect disease mechanisms and streamline translational workflows for cardiovascular research.

• MK-0812: Advancing Precision in Monocyte Trafficking Inhibit

  2026-06-30

  Explore how MK-0812, a potent CCR2 antagonist, enables precise inhibition of monocyte trafficking for advanced inflammation and MASH research. This article integrates mechanistic insights and protocol guidance, building on recent breakthroughs while offering practical strategies distinct from prior reviews.

• Intestinal TM6SF2 Protects Against MASH via Gut–Liver Axis M

  2026-06-30

  This study uncovers a protective role for intestinal TM6SF2 in metabolic dysfunction-associated steatohepatitis (MASH), acting through the gut–liver axis. By demonstrating how epithelial TM6SF2 deficiency triggers gut barrier dysfunction, microbial dysbiosis, and hepatic inflammation, the findings highlight new intervention targets for MASH.

• Lopinavir (ABT-378): Precision Tools for HIV and Antiviral R

  2026-06-29

  Lopinavir (ABT-378) stands out for its unrivaled HIV protease inhibition, proven efficacy in serum-rich assays, and demonstrated cross-viral potential against emerging threats like MERS-CoV. Discover how researchers leverage this compound from APExBIO for robust, mutation-resistant workflows and troubleshooting in both classic and cutting-edge antiviral studies.

• Histone H4K12 Lactylation Drives TNBC Progression via SLFN5

  2026-06-29

  This study uncovers a novel epigenetic mechanism in triple-negative breast cancer (TNBC), linking histone H4K12 lactylation to malignancy progression through the downregulation of SLFN5. By employing metabolic inhibitors such as sodium oxamate, the research demonstrates how targeting lactate-driven histone modifications can modulate tumor cell fate, suggesting new avenues for cancer metabolism research.

• Jiedu Xiaozheng Yin Modulates Macrophage Phenotype via TLR4

  2026-06-28

  Liu et al. demonstrate that Jiedu Xiaozheng Yin (JXY) suppresses colitis-associated colorectal cancer (CAC) progression by promoting M1 macrophage polarization through the TLR4 pathway. This mechanistic insight expands the repertoire of immunomodulatory strategies for CAC, suggesting the TLR4 signaling axis as a promising therapeutic target.

• IL-36/IL-36R Axis and NETosis in Psoriasis: Mechanistic Insi

  2026-06-27

  The referenced study elucidates how TLR ligands and purinergic signaling synergize to drive neutrophil extracellular trap (NET) formation, with IL-36/IL-36R signaling amplifying psoriatic skin inflammation. These findings highlight new avenues for targeting IL-36 and NETosis in the treatment of psoriasis.

• Capsaicin (E)-Capsaicin: Novel Insights on TRPV1 and Itch Ci

  2026-06-26

  Explore the unique mechanisms of Capsaicin (E)-Capsaicin in TRPV1 ion channel activation, focusing on its emerging role in chronic dermatitis and sensory neuron modulation. This article delivers in-depth analysis and practical guidance for advanced pain and itch research.

• Prestained Protein Marker (Triple Color, EDTA Free, 10-250 k

  2026-06-26

  The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) provides clearly visible molecular weight standards for SDS-PAGE and Western blotting, allowing for accurate monitoring of protein separation and transfer. This marker is best suited for workflows requiring compatibility with Phosbind SDS-PAGE or fluorescent membrane imaging, and should not be used in workflows where EDTA is required or where its visible color bands may interfere with detection.

• SB 202190: Precision p38 MAP Kinase Inhibitor for Cancer Mod

  2026-06-25

  SB 202190 empowers bench researchers with selective, potent inhibition of p38α/β MAPKs, enabling precise dissection of inflammation and tumor-immunity pathways. This article translates the latest colorectal cancer organoid-Treg co-culture findings into actionable workflows, protocol refinements, and troubleshooting insights for disease modeling.

• Carrier-Free Triterpene Prodrugs for Targeted OSCC Chemother

  2026-06-25

  This study presents a carrier-free, self-assembled prodrug system using glycyrrhetinic acid and ginsenoside Rh2 for targeted oral squamous cell carcinoma (OSCC) chemotherapy. By leveraging a ROS-responsive linker and dual triterpene synergy, the approach enhances tumor selectivity and drug release efficiency, offering a promising direction for low-toxicity natural product-based chemotherapeutics.

458 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page